Chinese Biotech Firms Leverage AI in Global Pharmaceutical Deals
Chinese biotech companies are increasingly securing major international agreements, with recent deals involving CSPC Pharmaceutical, RemeGen, and Haisco Pharmaceutical Group reaching billions of dollars. Haisco granted AbbVie rights to develop and market pain drug molecules outside China, reflecting a strategic move beyond manufacturing into innovation. Artificial intelligence is accelerating this transformation in drug discovery and development. Tony Ren of Macquarie Capital notes China's growing role in the global pharmaceutical value chain, which includes research, clinical trials, manufacturing, and commercialization stages. This shift positions China to potentially ascend to the industry's top tier within three to five years.
Key facts
- Chinese biotech firms are striking global deals worth billions of dollars.
- CSPC Pharmaceutical and RemeGen secured out-licensing agreements worth up to US$18.5 billion and US$5.6 billion respectively.
- Haisco Pharmaceutical Group made deals including one worth up to US$745 million with AbbVie.
- Haisco granted AbbVie rights to develop, manufacture, and sell pain drug molecules outside China.
- The deals signal a shift from low-cost manufacturing to higher-value innovation in China's biotech sector.
- Artificial intelligence is reshaping drug discovery and development, accelerating China's industry transformation.
- Tony Ren, head of Asia Healthcare Research at Macquarie Capital, predicts China's role in the global drug value chain will grow over the next three to five years.
- The pharmaceutical value chain includes research and development, clinical trials, manufacturing, and commercialization stages.
Entities
Institutions
- CSPC Pharmaceutical
- RemeGen
- Haisco Pharmaceutical Group
- AbbVie
- Macquarie Capital
- McKinsey
Locations
- China
- Beijing
- Hong Kong
- Japan